Aon Names Colliers International Platinum Level Best Employer in Canada

Firm earns prestigious recognition for excellence in employee engagement, leadership and performance culture

TORONTO, Nov. 09, 2017 (GLOBE NEWSWIRE) — Aon has named Colliers International a Platinum Level Best Employer in Canada.…

USSOCOM Awards Vricon Foreign Comparative Test Contract

Vricon to increase the resolution and accuracy of SOCOM’s 3D geospatial data

McLean, Virginia, Nov. 09, 2017 (GLOBE NEWSWIRE) — The US Special Operations Command (USSOCOM) awarded Vricon a contract for a Foreign Comparative Test for commercial data, software, and testing to increase the resolution and accuracy of the Command’s 3D geospatial data. …

Nasdaq Wins RiskTech100® Best Operational Risk & GRC Category

Awarded by Chartis Research, the accolade spotlights the major players in risk technology 

NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) — Nasdaq, Inc. (Nasdaq:NDAQ), one of the world’s leading Governance, Risk management and Compliance (GRC) solution providers, has won the Best Operational Risk & GRC provider at the RiskTech100® 2018 awards.

Disruptive Semiconductor Technology Leader Luxcore Signs Multi-year Colocation Deal with INAP

Luxcore selects INAP to support their ground breaking second generation LambdaRouterTM — the first full wavelength optical router.

INAP chosen for its global presence in strategic markets, carrier neutrality and signature Performance IPTM service.

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

  • Top-line results are expected to be announced in mid-2018
  • The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is evaluating the safety and efficacy of RHB-104 in 331 subjects with moderately to severely active Crohn’s disease
  • Worldwide sales of Crohn’s disease therapies exceeded $7.6 billion in 2016
  • A pivotal Phase III study with RHB-104 for Nontuberculous Mycobacteria (NTM) infections, with Fast-Track development status, is planned to be initiated in H1/2018          

TEL-AVIV, Israel and RALEIGH, N.C., Nov.

VistaJet Customers Grow by 50% in the Middle East as the Company Expands Its Reach

The leader in global business aviation increases its offering to continue positive momentum in the region

  • New Program hours doubled year over year
  • New Program customers rose by 50% year over year
  • Full flying service now available in and out of Saudi Arabia as expansion continues
  • Results follow $150 million investment from Rhône Capital    

DUBAI, United Arab Emirates, Nov.

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO).